Dramedilol

This classification denotes a vasodilating agent with the molecular formula C20H29N5O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8PW276HX8U, chemically known as acetone (- )-(6(3-((3,4-dimethoxyphenethyl)amino)-2-hydroxypropoxy)-3-pyridazinyl)hydrazone. but generally known as dramedilol, which bears US NIH Compound Identifier 208896. European Medicines Agency schedules Dramedilol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06396MIG. The term DRAMEDILOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). DRAMEDILOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dramedilol under HS 29339990 and SITC 51577. As of Q4 2014, DRAMEDILOL remains the US FDA Preferred Term for this commodity. Dramedilol bears US NLM identifiers UMLS ID C1880407 and NCI Concept Code C65478. SMILES: OC(CNCCc1cc(OC)c(OC)cc1)COc1nnc(N/N=C(/C)C)cc1.